MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

14.92 -0.06 (-0.40%)
Streaming Delayed Price Updated: 1:41 PM EDT, Jun 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Bausch + Lomb (NYSE:BLCO) Misses Q1 Sales Targets, Stock Drops 10.4%
Eyecare company Bausch + Lomb (NYSE:BLCO) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3.5% year on year to $1.14 billion. On the other hand, the company’s full-year revenue... 
Via StockStory
News headline image
Bausch + Lomb Announces First-Quarter 2025 Results
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Earnings Scheduled For April 30, 2025 ↗
 
Via Benzinga
News headline image
Bausch + Lomb (BLCO) Reports Q1: Everything You Need To Know Ahead Of Earnings
Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings tomorrow before market open. Here’s what you need to know. 
Via StockStory
Topics World Trade
News headline image
Earnings Scheduled For February 19, 2025 ↗
 
Via Benzinga
News headline image
Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Bausch + Lomb Returning enVista® Intraocular Lenses to Market Following Voluntary Recall
From Bausch + Lomb Corporation
Via Business Wire
News headline image
3 Reasons to Sell BLCO and 1 Stock to Buy Instead
Bausch + Lomb has gotten torched over the last six months - since October 2024, its stock price has dropped 41.5% to $12.06 per share. This might have investors contemplating their next move. 
Via StockStory
Topics Bankruptcy
News headline image
3 of Wall Street’s Favorite Stocks in the Doghouse
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Topics Firearms
News headline image
Q4 Earnings Roundup: Bausch + Lomb (NYSE:BLCO) And The Rest Of The Medical Devices & Supplies - Specialty Segment
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Bausch + Lomb (NYSE:BLCO) and its peers. 
Via StockStory
News headline image
Q4 Earnings Highs And Lows: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Haemonetics (NYSE:HAE) and the best and... 
Via StockStory
News headline image
Why Bausch + Lomb (BLCO) Shares Are Plunging Today
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 6.7% in the morning session after Wells Fargo downgraded the stock's rating from Buy to Hold. The firm cited concerns related to the "voluntary... 
Via StockStory
Topics Artificial Intelligence Initial Public Offering
News headline image
Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Why Bausch + Lomb (BLCO) Stock Is Nosediving
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 10.6% in the afternoon session after the company announced the voluntary recall of intraocular lenses on its enVista platform. The recall was... 
Via StockStory
Topics Artificial Intelligence Initial Public Offering
News headline image
Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30
From Bausch + Lomb Corporation
Via Business Wire
News headline image
3 Healthcare Stocks in the Doghouse
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
News headline image
Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United States
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Medical Devices & Supplies - Specialty Stocks Q4 In Review: Globus Medical (NYSE:GMED) Vs Peers
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers. 
Via StockStory
News headline image
3 Stocks Under $50 Walking a Fine Line
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
News headline image
Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises ↗
The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China. 
Via Stocktwits
Topics Earnings
News headline image
Globus Medical (GMED) Q4 Earnings: What To Expect
Medical device company Globus Medical (NYSE:GMED) will be announcing earnings results tomorrow after the bell. Here’s what to expect. 
Via StockStory
News headline image
Earnings To Watch: Integer Holdings (ITGR) Reports Q4 Results Tomorrow
Medical technology company Integer Holdings (NYSE:ITGR) will be announcing earnings results tomorrow before market hours. Here’s what you need to know. 
Via StockStory
News headline image
Bausch + Lomb’s (NYSE:BLCO) Q4: Beats On Revenue
Eyecare company Bausch + Lomb (NYSE:BLCO) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 9.1% year on year to $1.28 billion. On the other hand, the company’s full-year... 
Via StockStory
News headline image
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect
Eyecare company Bausch + Lomb (NYSE:BLCO) will be announcing earnings results tomorrow morning. Here’s what to expect. 
Via StockStory
News headline image
Deal Dispatch: PharmChem Forgoes Banker To Run Sale, TGI Fridays Sells 19 Restaurants For $3.1 Million ↗
Bausch + Lomb's efforts to sell have so far been unsuccessful. Meanwhile, KKR is aggressively pursuing a deal for Fuji Soft. 
Via Benzinga
News headline image
Bausch + Lomb Provides Update on Potential Sale
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Aehr Test Systems Posts Weak Results, Joins Trump Media & Technology Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
Topics Government
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story